You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

352 Results
Guidelines and Advice
Status: Current
ID: GL 2-30a
Version: N/A
Mar 2020
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    lomustine
New Drug Funding Program
    Bevacizumab (Biosimilar) - In Combination with Lomustine for Recurrent Glioblastoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lomustine,
bevacizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2024
Document
Apr 2020
Cette page s’adresse aux personnes ayant récemment reçu un diagnostic de leucémie aiguë lymphoblastique (LAL)
 
Document
Sep 2020
Document
Sep 2020
Cancer facts
Oct 2020
Guidelines and Advice
Status: Current
Apr 2021
Trouvez des liens vers des pages d’information sur les soins de cancérologie offerts en Ontario pendant la pandémie de COVID-19.

Pages